** Brokerage Needham raises PT on medical device maker iRhythm Technologies' shares to $112 from $96; maintains "buy" rating
** Raised PT represents 14.8% upside to stock's last close
** Brokerage forecasts Q4 revenue to be more than $160 mln vs est $157.5 mln - LSEG
** IRTC's heart monitoring devices, Zio monitor and Zio AT, drove company's strength in revenue forecast - brokerage
** Company forecast 2025 revenue between $675 mln and $685 mln, brokerage expects company will make "further progress on ramping profitability"
** Company's shares fell ~11% in 2024
(Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。